PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20121886-0	2010	The effect of rosiglitazone on insulin sensitivity and mid-thigh low-density muscle in patients with Type 2 diabetes.	Rosiglitazone	14-27	insulin	Homo sapiens	31-38	
20121886-5	2010	RESULTS: Twelve weeks" rosiglitazone treatment resulted in improved insulin resistance despite increases in body weight and BMI.	Rosiglitazone	23-36	insulin	Homo sapiens	68-75	
20121886-9	2010	CONCLUSIONS: Rosiglitazone treatment resulted in an improvement of insulin responsiveness in Type 2 diabetic subjects, which was associated with the redistribution of visceral and subcutaneous adipose tissue, an increase in TLDMA, and changes in serum adipocytokine levels.	Rosiglitazone	13-26	insulin	Homo sapiens	67-74	
20121886-10	2010	Further studies are needed to elucidate the insulin sensitizing mechanism of rosiglitazone on peripheral skeletal muscles.	Rosiglitazone	77-90	insulin	Homo sapiens	44-51